Highly-specific memory B cells generation after the 2^nd dose of BNT162b2 vaccine compensate for the decline of serum antibodies and absence of mucosal IgA

AbstractSpecific memory B cells and antibodies are reliable read-out of vaccine efficacy. We analyzed these biomarkers after one and two doses of BNT162b2 vaccine. The second dose significantly increases the level of highly-specific memory B cells and antibodies. Two months after the second dose, specific antibody levels decline, but highly specific memory B cells continue to increase thus predicting a sustained protection from COVID-19. Graphical Abstract